Although voriconazole has been shown to interact with calcineurin inhibitors, this interaction has not been thoroughly examined. The purpose of this study was to evaluate the drug interaction between voriconazole and calcineurin inhibitors among recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-one recipients of allogeneic HSCT were evaluated. Those recipients had been on CsA (n ¼ 10) or tacrolimus (n ¼ 11) when voriconazole (400 mg per day orally, or 8 mg/kg per day, i.v.) was initiated. Trough concentrations of calcineurin inhibitors were measured before and periodically after initiating voriconazole to determine the concentration/dose (C/D) ratio of calcineurin inhibitors. Median C/D ratio significantly increased by initiating voriconazole: from 86.0 (range, 43.5-178.8) to 120.2 (range, 86.1-379.4) in CsA (Po0.05), and from 595.9 (range, 51.3-1643.3) to 890.7 (range, 94.1-4658.3) (ng/ml)/(mg/kg) in tacrolimus (Po0.01). Median increases in the C/D ratio did not differ significantly between CsA and tacrolimus (82.1%, ranging from À9.4 to 266.9% vs 115.6%, ranging from 25.4 to 307.6%). These results indicate that voriconazole alters the blood concentration of calcineurin inhibitors with a wide range of interindividual variability after allogeneic HSCT. Dose adjustment of calcineurin inhibitors on initiating voriconazole should not be decided uniformly, but determined on an individual basis by close monitoring of their blood concentrations.
Introduction
Patients with hematological malignancies receiving chemotherapy, particularly those undergoing hematopoietic stem cell transplantation (HSCT), are at high risk of developing invasive fungal disease (IFD). Fluconazole has been routinely recommended for the prophylaxis and treatment of IFD after HSCT. 1 However, because of the increasing incidence of mold infection, mainly Aspergillus species, effective prophylaxis and treatment of Aspergillus species has been required. 2, 3 Voriconazole, a novel triazole antifungal agent, has a potent activity against a broad spectrum of fungi, including yeasts and molds. Voriconazole has been reported to improve the survival of patients with invasive aspergillosis as compared with amphotericin B, and has become the first option for the treatment of invasive aspergillosis. 4, 5 Voriconazole is metabolized by cytochrome P-450 (CYP) enzymes, namely CYP 2C9, 2C19 and 3A4. 5 In vitro studies have demonstrated that voriconazole could be a substrate as well as an inhibitor of these enzymes. 6 Therefore, its drug interaction with a variety of agents metabolized by these enzymes, including immunosuppressive agents (CsA, tacrolimus and sirolimus), has been recognized. Its drug interaction with CsA and tacrolimus is especially problematic, because calcineurin inhibitors have a narrow therapeutic window. [5] [6] [7] [8] However, the drug interaction between voriconazole and calcineurin inhibitors has been systematically examined only in a limited number of renal transplant recipients (CsA) and in healthy subjects (tacrolimus), and documented sporadically in a few case reports. [7] [8] [9] [10] [11] [12] In particular, the drug interaction between voriconazole and tacrolimus has not been systematically evaluated in patients to this date. In spite of such limited data, a uniform dose reduction of calcineurin inhibitors on initiating voriconazole (1/2 for CsA, 1/3 for tacrolimus) has been recommended by the manufacturer. 13 Although the evaluation of drug interaction between voriconazole and calcineurin inhibitors is highly relevant for clinical practice because of the increase in the use of voriconazole after allogeneic HSCT, there has been no such evaluation in recipients of allogeneic HSCT except for one case report. 12 This prompted us to study the drug interaction between voriconazole and calcineurin inhibitors in 21 recipients of allogeneic HSCT to confirm the appropriateness of uniform dose modification of calcineurin inhibitors on initiating voriconazole in this patient population.
Patients and methods

Patient selection and drug administration
Recipients of allogeneic HSCT who had already been on a steady dose of calcineurin inhibitors (CsA or tacrolimus), and were started on oral or i.v. voriconazole for the treatment or prophylaxis of aspergillosis, were included in this study. Patient's blood levels of CsA or tacrolimus were stable when voriconazole was initiated. Oral voriconazole was administered under fasting conditions at a maintenance dose of 200 mg per body every 12 h after two initial doses of 300 mg per body 12 h apart. The median maintenance dose of voriconazole was 4.0 mg/kg per day (range, 3.1-4.6) every 12 h in patients who received voriconazole orally. Patients who received voriconazole orally did not have gastrointestinal symptoms. Voriconazole (i.v.) was administered at a dose of 4 mg/kg every 12 h after two initial doses of 6 mg/kg 12 h apart.
Determination of concentration/dose ratio of calcineurin inhibitors
Whole blood levels of CsA and tacrolimus were measured using standard fluorescence polarization immunoassay and microparticle enzyme immunoassay, respectively. Blood levels of calcineurin inhibitors were measured just before and every 1-2 days after initiating voriconazole for 7-10 days. Each physician decreased doses of the calcineurin inhibitors in response to rising levels every 1-2 days. The concentration/dose (C/D; (ng/ml)/(mg/kg)) ratio of calcineurin inhibitors was calculated 7-10 days after initiating voriconazole when the increased blood levels of calcineurin inhibitors had stabilized. The increase in the C/D ratio after initiating voriconazole was determined in comparison with that just before initiating the drug.
Statistical analysis
The Wilcoxon signed-rank test was used to compare the difference in the C/D ratio before and after initiating voriconazole. The Mann-Whitney U-test was used to compare the difference in percentage of the increase in C/D ratio between CsA-and tacrolimus-administered patients. P-values less than 0.05 were accepted as statistically significant.
Results
Patients
A total of 21 patients were evaluated, and their characteristics are shown in Table 1 . Of them, 10 patients had been on CsA, and 11 patients had been on tacrolimus. The median post transplant day when voriconazole was initiated was 106 (range, 10-580). Voriconazole was given orally in 11 patients, and i.v. in 10 patients. All patients had a stable renal and hepatic function during the administration of voriconazole. Voriconazole interaction with calcineurin inhibitors T Mori et al
Effect of voriconazole administration on C/D ratio of calcineurin inhibitors
Blood levels of CsA and tacrolimus increased steadily after initiating voriconazole in all patients except for one patient in whom voriconazole did not affect the levels of CsA. The median C/D ratio of CsA after initiating voriconazole was 120.2 (ng/ml)/(mg/kg) with a range of 86.1-379.4, which was significantly higher than that before initiating voriconazole (86.0 (ng/ml)/(mg/kg) with a range of 43.5-178.8; Po0.05; Table 2 ). The median C/D ratio of tacrolimus after initiating voriconazole was 890.7 (ng/ml)/(mg/kg) with a range of 94.1-4658.3, which was significantly higher than that before initiating voriconazole (595.9 with a range of 51.3-1643.3; Po0.01; Table 2 ). Median increases were 82.1% (range, À9.4-266.9) and 115.6% (range, 25.4-307.6) in CsA-and tacrolimus-administered patients, respectively. The difference in increases between CsA and tacrolimus was not significant (P ¼ 0.14). Neither the route of voriconazole administration (i.v. or oral) nor the gender significantly affected the increase in C/D ratio (P ¼ 0.12 and 0.60, respectively). No significant adverse effects associated with increased level of calcineurin inhibitors were observed.
Discussion
In this study, we demonstrated that orally or i.v. administered voriconazole exerts a clinically significant drug interaction with calcineurin inhibitors in allogeneic HSCT recipients, resulting in a significant increase in the blood concentration of calcineurin inhibitors. The results were consistent with those of two previous reports showing its drug interaction with CsA in 7 renal transplant recipients and with tacrolimus in 14 healthy individuals. 7, 8 In spite of the limited number of subjects in the previous studies, uniform dose reduction of calcineurin inhibitors has been recommended for patients on these drugs who are initiating voriconazole; the purpose is to prevent the toxicity of calcineurin inhibitors from reaching the toxic threshold. 13 In decreasing the dose of calcineurin inhibitors according to the drug interaction, physicians should always weigh the risks of the toxicity of calcineurin inhibitors and the development of GVHD or graft rejection in solid organ transplantation. However, our results showed that there was considerable interpatient variability in the magnitude of drug interaction in terms of increases in the C/D ratio of calcineurin inhibitors. Therefore, we think that the dose reduction of calcineurin inhibitors should not be decided uniformly, but should instead be determined on an individual basis by careful and periodic monitoring of their blood concentrations.
Previous studies have assessed the magnitude of drug interaction between voriconazole and calcineurin inhibitors by comparing the concentrations of calcineurin inhibitors before and after initiating voriconazole, in some cases using the area under the concentration-time curve, or by presenting the dose reduction rate of calcineurin inhibitors determined by each physician. [7] [8] [9] [10] [11] [12] However, such approaches are unable to evaluate the exact drug interaction quantitatively, because they focused either on the concentration or the dose of calcineurin inhibitors. In contrast, we used the C/D ratio ((ng/ml)/(mg/kg)) for the quantitative evaluation of drug interaction, which reflects both the concentration and dose of calcineurin inhibitors. We believe that the present results using this method could provide data of more clinical relevance.
The manufacturer's recommendation sets uniform dose reduction rates for calcineurin inhibitors on initiating voriconazole. This recommendation is based on the results of two small studies performed separately. 7, 8 As opposed to the two previous studies, we found that the impact of voriconazole on the concentration of CsA and tacrolimus did not differ significantly. Thus, the manufacturer's recommendation gave the physicians the misleading impression that voriconazole had a greater effect on tacrolimus than on CsA.
The reasons accounting for the notable interindividual difference in the drug interaction between voriconazole and calcineurin inhibitors remains to be elucidated. One possible explanation is the difference in the activity of CYP among patients. Voriconazole is metabolized by three separate enzymes, CYP 2C9, 2C19 and 3A4. 5 The CYP 2C19, the major enzyme responsible for the metabolism of voriconazole, exhibits genetic polymorphisms, so that voriconazole could be metabolized to a greater or lesser extent among different individuals, resulting in significant differences in its concentration of voriconazole. Because voriconazole acts as an inhibitor as well as a substrate of CYP3A4, it is also plausible that the higher the concentration of voriconazole, the more the activity of CYP 3A4 is reduced. Together with the interindividual difference in the blood concentration of voriconazole documented in allogeneic HSCT recipients, 14 it is suggested that the interindividual difference in the metabolism of voriconazole is critical in its drug interaction with calcineurin inhibitors. We conclude that the drug interaction between voriconazole and calcineurin inhibitors varies significantly among patients; thus, the dose adjustment of calcineurin inhibitors on initiating or discontinuing voriconazole should not be decided uniformly. Rather, close monitoring of the concentration in each individual is necessary to guide dosage adjustments with the goal of minimizing doserelated toxicity and maximizing efficacy of calcineurin inhibitors. The relationship between the blood concentration of voriconazole and its drug interaction with calcineurin inhibitors should be examined in a future study.
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